目次

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET INTRODUCTION
2.1. Definition
2.2. Scope of the Study
2.2.1. Research Objective
2.2.2. Assumptions
2.2.3. Limitations

3. RESEARCH METHODOLOGY
3.1. Overview
3.2. Data Mining
3.3. Secondary Research
3.4. Primary Research
3.4.1. Primary Interviews and Information Gathering Process
3.4.2. Breakdown of Primary Respondents
3.5. Forecasting Model
3.6. Market Size Estimation
3.6.1. Bottom-Up Approach
3.6.2. Top-Down Approach
3.7. Data Triangulation
3.8. Validation

4. MARKET DYNAMICS
4.1. Overview
4.2. Drivers
4.3. Restraints
4.4. Opportunities

5. MARKET FACTOR ANALYSIS
5.1. Value Chain Analysis
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining Power of Suppliers
5.2.2. Bargaining Power of Buyers
5.2.3. Threat of New Entrants
5.2.4. Threat of Substitutes
5.2.5. Intensity of Rivalry
5.3. COVID-19 Impact Analysis
5.3.1. Market Impact Analysis
5.3.2. Regional Impact
5.3.3. Opportunity and Threat Analysis

6. GLOBAL RNA BASED THERAPEUTICS MARKET,BY TYPE
6.1. Overview
6.2. RNA Interference (RNAi)
6.3. RNA Antisense

7. GLOBAL RNA BASED THERAPEUTICS MARKET,BY APPLICATION
7.1. Overview
7.2. Genetic Disorders
7.3. Auto immune disorders

8. GLOBAL RNA BASED THERAPEUTICS MARKET,BY END USER
8.1. Overview
8.2. Research Institutes
8.3. Hospitals & Clinics

9. GLOBAL RNA BASED THERAPEUTICS MARKET, BY REGION
9.1. Overview
9.1. North America
9.1.1. US
9.1.2. Canada
9.2. Europe
9.2.1. Germany
9.2.2. France
9.2.3. UK
9.2.4. Italy
9.2.5. Spain
9.2.6. Rest of Europe
9.3. Asia-Pacific
9.3.1. China
9.3.2. India
9.3.3. Japan
9.3.4. South Korea
9.3.5. Australia
9.3.6. Rest of Asia-Pacific
9.4. Rest of the World
9.4.1. Middle East
9.4.2. Africa
9.4.3. Latin America

10. COMPETITIVE LANDSCAPE
10.1. Overview
10.2. Competitive Analysis
10.3. Market Share Analysis
10.4. Major Growth Strategy in the Global RNA Based Therapeutics Market,
10.5. Competitive Benchmarking
10.6. Leading Players in Terms of Number of Developments in the Global RNA Based Therapeutics Market,
10.7. Key developments and Growth Strategies
10.7.1. New ProductLaunch/Service Deployment
10.7.2. Merger &Acquisitions
10.7.3. Joint Ventures
10.8. Major Players Financial Matrix
10.8.1. Sales & Operating Income,2022
10.8.2. Major Players R&D Expenditure.2022

11. COMPANY PROFILES
11.1. Arrowhead Pharmaceuticals
11.1.1. Company Overview
11.1.2. Financial Overview
11.1.3. Products Offered
11.1.4. Key Developments
11.1.5. SWOT Analysis
11.1.6. Key Strategies
11.2. Arbutus Biopharma Corporation
11.2.1. Company Overview
11.2.2. Financial Overview
11.2.3. Products Offered
11.2.4. Key Developments
11.2.5. SWOT Analysis
11.2.6. Key Strategies
11.3. Benitec Biopharma Inc.
11.3.1. Company Overview
11.3.2. Financial Overview
11.3.3. Products Offered
11.3.4. Key Developments
11.3.5. SWOT Analysis
11.3.6. Key Strategies
11.4. Silence Therapeutics plc
11.4.1. Company Overview
11.4.2. Financial Overview
11.4.3. Products Offered
11.4.4. Key Developments
11.4.5. SWOT Analysis
11.4.6. Key Strategies
11.5. Ionis Pharmaceuticals
11.5.1. Company Overview
11.5.2. Financial Overview
11.5.3. Products Offered
11.5.4. Key Developments
11.5.5. SWOT Analysis
11.5.6. Key Strategies
11.6. Gradalis, Inc.
11.6.1. Company Overview
11.6.2. Financial Overview
11.6.3. Products Offered
11.6.4. Key Developments
11.6.5. SWOT Analysis
11.6.6. Key Strategies
11.7. Biogen, Inc
11.7.1. Company Overview
11.7.2. Financial Overview
11.7.3. Products Offered
11.7.4. Key Developments
11.7.5. SWOT Analysis
11.7.6. Key Strategies
11.8. Alnylam Pharmaceuticals, Inc.
11.8.1. Company Overview
11.8.2. Financial Overview
11.8.3. Products Offered
11.8.4. Key Developments
11.8.5. SWOT Analysis
11.8.6. Key Strategies
11.9. Genzyme (Sanofi)
11.9.1. Company Overview
11.9.2. Financial Overview
11.9.3. Products Offered
11.9.4. Key Developments
11.9.5. SWOT Analysis
11.9.6. Key Strategies
11.10. Sarepta Therapeutics
11.10.1. Company Overview
11.10.2. Financial Overview
11.10.3. Products Offered
11.10.4. Key Developments
11.10.5. SWOT Analysis
11.10.6. Key Strategies

12. APPENDIX
12.1. References
12.2. Related Reports

LIST OF TABLES
TABLE 1 GLOBAL RNA BASED THERAPEUTICS MARKET, SYNOPSIS, 2018-2032
TABLE 2 GLOBAL RNA BASED THERAPEUTICS MARKET, ESTIMATES &FORECAST, 2018-2032(USD BILLION)
TABLE 3 GLOBAL RNA BASED THERAPEUTICS MARKET,BY TYPE, 2018-2032 (USD BILLION)
TABLE 4 GLOBAL RNA BASED THERAPEUTICS MARKET,BY APPLICATION, 2018-2032 (USD BILLION)
TABLE 5 GLOBAL RNA BASED THERAPEUTICS MARKET,BY END USER, 2018-2032 (USD BILLION)
TABLE 6 NORTH AMERICA: RNA BASED THERAPEUTICS MARKET,BY TYPE, 2018-2032 (USD BILLION)
TABLE 7 NORTH AMERICA: RNA BASED THERAPEUTICS MARKET,BY APPLICATION, 2018-2032 (USD BILLION)
TABLE 8 NORTH AMERICA: RNA BASED THERAPEUTICS MARKET,BY END USER, 2018-2032 (USD BILLION)
TABLE 9 US: RNA BASED THERAPEUTICS MARKET,BY TYPE, 2018-2032 (USD BILLION)
TABLE 10 US: RNA BASED THERAPEUTICS MARKET,BY APPLICATION, 2018-2032 (USD BILLION)
TABLE 11 US: RNA BASED THERAPEUTICS MARKET,BY END USER, 2018-2032 (USD BILLION)
TABLE 12 CANADA: RNA BASED THERAPEUTICS MARKET,BY TYPE, 2018-2032 (USD BILLION)
TABLE 13 CANADA: RNA BASED THERAPEUTICS MARKET,BY APPLICATION, 2018-2032 (USD BILLION)
TABLE 14 CANADA: RNA BASED THERAPEUTICS MARKET,BY END USER, 2018-2032 (USD BILLION)
TABLE 1 EUROPE: RNA BASED THERAPEUTICS MARKET,BY TYPE, 2018-2032 (USD BILLION)
TABLE 2 EUROPE: RNA BASED THERAPEUTICS MARKET, BY APPLICATION , 2018-2032 (USD BILLION)
TABLE 3 EUROPE: RNA BASED THERAPEUTICS MARKET, BY END USER, 2018-2032 (USD BILLION)
TABLE 4 GERMANY: RNA BASED THERAPEUTICS MARKET,BY TYPE,2018-2032 (USD BILLION)
TABLE 5 GERMANY: RNA BASED THERAPEUTICS MARKET, BY APPLICATION, 2018-2032 (USD BILLION)
TABLE 6 GERMANY: RNA BASED THERAPEUTICS MARKET, BY END USER , 2018-2032 (USD BILLION)
TABLE 7 FRANCE: RNA BASED THERAPEUTICS MARKET,BY TYPE, 2018-2032 (USD BILLION)
TABLE 8 FRANCE: RNA BASED THERAPEUTICS MARKET, BY APPLICATION, 2018-2032 (USD BILLION)
TABLE 9 FRANCE: RNA BASED THERAPEUTICS MARKET, BY END USER, 2018-2032 (USD BILLION)
TABLE 10 ITALY: RNA BASED THERAPEUTICS MARKET,BY TYPE, 2018-2032 (USD BILLION)
TABLE 11 ITALY: RNA BASED THERAPEUTICS MARKET, BY APPLICATION, 2018-2032 (USD BILLION)
TABLE 12 ITALY: RNA BASED THERAPEUTICS MARKET, BY END USER, 2018-2032 (USD BILLION)
TABLE 13 SPAIN: RNA BASED THERAPEUTICS MARKET,BY TYPE, 2018-2032 (USD BILLION)
TABLE 14 SPAIN: RNA BASED THERAPEUTICS MARKET, BY APPLICATION, 2018-2032 (USD BILLION)
TABLE 15 SPAIN: RNA BASED THERAPEUTICS MARKET, BY END USER, 2018-2032 (USD BILLION)
TABLE 16 UK: RNA BASED THERAPEUTICS MARKET,BY TYPE, 2018-2032 (USD BILLION)
TABLE 17 UK: RNA BASED THERAPEUTICS MARKET, BY APPLICATION, 2018-2032 (USD BILLION)
TABLE 18 UK: RNA BASED THERAPEUTICS MARKET, BY END USER, 2018-2032 (USD BILLION)
TABLE 19 REST OF EUROPE: RNA BASED THERAPEUTICS MARKET,BY TYPE, 2018-2032 (USD BILLION)
TABLE 20 REST OF EUROPE: RNA BASED THERAPEUTICS MARKET, BY APPLICATION, 2018-2032 (USD BILLION)
TABLE 21 REST OF EUROPE: RNA BASED THERAPEUTICS MARKET, BY END USER, 2018-2032 (USD BILLION)
TABLE 22 ASIA-PACIFIC: RNA BASED THERAPEUTICS MARKET,BY TYPE, 2018-2032 (USD BILLION)
TABLE 23 ASIA-PACIFIC: RNA BASED THERAPEUTICS MARKET, BY APPLICATION, 2018-2032 (USD BILLION)
TABLE 24 ASIA-PACIFIC: RNA BASED THERAPEUTICS MARKET, BY END USER, 2018-2032 (USD BILLION)
TABLE 25 JAPAN: RNA BASED THERAPEUTICS MARKET,BY TYPE, 2018-2032 (USD BILLION)
TABLE 26 JAPAN: RNA BASED THERAPEUTICS MARKET, BY APPLICATION, 2018-2032 (USD BILLION)
TABLE 27 JAPAN: RNA BASED THERAPEUTICS MARKET, BY END USER, 2018-2032 (USD BILLION)
TABLE 28 CHINA: RNA BASED THERAPEUTICS MARKET,BY TYPE, 2018-2032 (USD BILLION)
TABLE 29 CHINA: RNA BASED THERAPEUTICS MARKET, BY APPLICATION, 2018-2032 (USD BILLION)
TABLE 30 CHINA: RNA BASED THERAPEUTICS MARKET, BY END USER, 2018-2032 (USD BILLION)
TABLE 31 INDIA: RNA BASED THERAPEUTICS MARKET,BY TYPE, 2018-2032 (USD BILLION)
TABLE 32 INDIA: RNA BASED THERAPEUTICS MARKET, BY APPLICATION, 2018-2032 (USD BILLION)
TABLE 33 INDIA: RNA BASED THERAPEUTICS MARKET, BY END USER, 2018-2032 (USD BILLION)
TABLE 34 AUSTRALIA: RNA BASED THERAPEUTICS MARKET,BY TYPE, 2018-2032 (USD BILLION)
TABLE 35 AUSTRALIA: RNA BASED THERAPEUTICS MARKET, BY APPLICATION, 2018-2032 (USD BILLION)
TABLE 36 AUSTRALIA: RNA BASED THERAPEUTICS MARKET, BY END USER, 2018-2032 (USD BILLION)
TABLE 37 SOUTH KOREA: RNA BASED THERAPEUTICS MARKET,BY TYPE, 2018-2032 (USD BILLION)
TABLE 38 SOUTH KOREA: RNA BASED THERAPEUTICS MARKET, BY APPLICATION, 2018-2032 (USD BILLION)
TABLE 39 SOUTH KOREA: RNA BASED THERAPEUTICS MARKET, BY END USER, 2018-2032 (USD BILLION)
TABLE 40 REST OF ASIA-PACIFIC: RNA BASED THERAPEUTICS MARKET,BY TYPE, 2018-2032 (USD BILLION)
TABLE 41 REST OF ASIA-PACIFIC: RNA BASED THERAPEUTICS MARKET, BY APPLICATION, 2018-2032 (USD BILLION)
TABLE 42 REST OF ASIA-PACIFIC: RNA BASED THERAPEUTICS MARKET, BY END USER, 2018-2032 (USD BILLION)
TABLE 43 REST OF THE WORLD: RNA BASED THERAPEUTICS MARKET,BY TYPE, 2018-2032 (USD BILLION)
TABLE 44 REST OF THE WORLD: RNA BASED THERAPEUTICS MARKET, BY APPLICATION, 2018-2032 (USD BILLION)
TABLE 45 REST OF THE WORLD: RNA BASED THERAPEUTICS MARKET, BY END USER, 2018-2032 (USD BILLION)
TABLE 46 MIDDLE EAST: RNA BASED THERAPEUTICS MARKET,BY TYPE, 2018-2032 (USD BILLION)
TABLE 47 MIDDLE EAST: RNA BASED THERAPEUTICS MARKET, BY APPLICATION, 2018-2032 (USD BILLION)
TABLE 48 MIDDLE EAST: RNA BASED THERAPEUTICS MARKET, BY END USER, 2018-2032 (USD BILLION)
TABLE 49 AFRICA: RNA BASED THERAPEUTICS MARKET,BY TYPE, 2018-2032 (USD BILLION)
TABLE 50 AFRICA: RNA BASED THERAPEUTICS MARKET, BY APPLICATION, 2018-2032 (USD BILLION)
TABLE 51 AFRICA: RNA BASED THERAPEUTICS MARKET, BY END USER, 2018-2032 (USD BILLION)
TABLE 52 LATIN AMERICA: RNA BASED THERAPEUTICS MARKET,BY TYPE, 2018-2032 (USD BILLION)
TABLE 53 LATIN AMERICA: RNA BASED THERAPEUTICS MARKET, BY APPLICATION, 2018-2032 (USD BILLION)
TABLE 54 LATIN AMERICA: RNA BASED THERAPEUTICS MARKET, BY END USER, 2018-2032 (USD BILLION)

LIST OF FIGURES
FIGURE 1 RESEARCH PROCESS
FIGURE 2 MARKET STRUCTURE FOR THE GLOBAL RNA BASED THERAPEUTICS MARKET
FIGURE 3 MARKET DYNAMICS FOR THE GLOBAL RNA BASED THERAPEUTICS MARKET
FIGURE 4 GLOBAL RNA BASED THERAPEUTICS MARKET, SHARE (%), BY TYPE, 2022
FIGURE 5 GLOBAL RNA BASED THERAPEUTICS MARKET, SHARE (%), BY APPLICATION, 2022
FIGURE 6 GLOBAL RNA BASED THERAPEUTICS MARKET, SHARE (%), BY END USER, 2022
FIGURE 7 GLOBAL RNA BASED THERAPEUTICS MARKET, SHARE (%), BY REGION, 2022
FIGURE 8 NORTH AMERICA: RNA BASED THERAPEUTICS MARKET, SHARE (%), BY REGION, 2022
FIGURE 9 EUROPE: RNA BASED THERAPEUTICS MARKET, SHARE (%), BY REGION, 2022
FIGURE 10 ASIA-PACIFIC: RNA BASED THERAPEUTICS MARKET, SHARE (%), BY REGION, 2022
FIGURE 11 REST OF THE WORLD: RNA BASED THERAPEUTICS MARKET, SHARE (%), BY REGION, 2022
FIGURE 12 GLOBAL RNA BASED THERAPEUTICS MARKET: COMPANY SHARE ANALYSIS, 2022 (%)
FIGURE 13 ARROWHEAD PHARMACEUTICALS: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 14 ARROWHEAD PHARMACEUTICALS: SWOT ANALYSIS
FIGURE 15 ARBUTUS BIOPHARMA CORPORATION.:FINANCIAL OVERVIEW SNAPSHOT
FIGURE 16 ARBUTUS BIOPHARMA CORPORATION.:SWOT ANALYSIS
FIGURE 17 BENITEC BIOPHARMA INC.:FINANCIAL OVERVIEW SNAPSHOT
FIGURE 18 BENITEC BIOPHARMA INC.:SWOT ANALYSIS
FIGURE 19 SILENCE THERAPEUTICS PLC.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 20 SILENCE THERAPEUTICS PLC.:SWOT ANALYSIS
FIGURE 21 IONIS PHARMACEUTICALS:FINANCIAL OVERVIEW SNAPSHOT
FIGURE 22 IONIS PHARMACEUTICALS:SWOT ANALYSIS
FIGURE 23 GRADALIS, INC..:FINANCIAL OVERVIEW SNAPSHOT
FIGURE 24 GRADALIS, INC..:SWOT ANALYSIS
FIGURE 25 BIOGEN, INC: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 26 BIOGEN, INC: SWOT ANALYSIS
FIGURE 27 ALNYLAM PHARMACEUTICALS, INC.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 28 ALNYLAM PHARMACEUTICALS, INC.: SWOT ANALYSIS
FIGURE 29 GENZYME (SANOFI).: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 30 GENZYME (SANOFI).: SWOT ANALYSIS
FIGURE 31 SAREPTA THERAPEUTICS.:FINANCIAL OVERVIEW SNAPSHOT
FIGURE 32 SAREPTA THERAPEUTICS.:SWOT ANALYSIS